Elevance Health, Inc. (NYSE:ELV) Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,859 shares of the company's stock after buying an additional 9,916 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.09% of Elevance Health worth $109,127,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ELV. Ameriprise Financial Inc. boosted its stake in shares of Elevance Health by 5.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,791,793 shares of the company's stock valued at $2,054,641,000 after buying an additional 190,118 shares during the period. Legal & General Group Plc raised its holdings in shares of Elevance Health by 2.9% in the 2nd quarter. Legal & General Group Plc now owns 2,247,091 shares of the company's stock valued at $1,217,607,000 after purchasing an additional 64,376 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Elevance Health by 34.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,062,706 shares of the company's stock worth $1,117,698,000 after purchasing an additional 523,910 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Elevance Health by 15.5% in the second quarter. First Eagle Investment Management LLC now owns 2,058,283 shares of the company's stock valued at $1,115,301,000 after buying an additional 275,708 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Elevance Health by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,867,551 shares of the company's stock valued at $1,011,888,000 after buying an additional 23,872 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company's stock.

Analysts Set New Price Targets

ELV has been the subject of several recent analyst reports. Barclays decreased their target price on Elevance Health from $622.00 to $501.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. TD Cowen reduced their target price on shares of Elevance Health from $589.00 to $484.00 and set a "buy" rating for the company in a report on Monday, October 21st. Raymond James set a $485.00 price objective on Elevance Health in a research note on Friday, October 18th. UBS Group cut their price target on Elevance Health from $605.00 to $555.00 and set a "buy" rating for the company in a research note on Friday, October 18th. Finally, Argus lowered shares of Elevance Health from a "buy" rating to a "hold" rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Elevance Health has an average rating of "Moderate Buy" and a consensus price target of $539.20.

Insider Buying and Selling at Elevance Health

In other news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the company's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $432.14, for a total value of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares in the company, valued at approximately $3,639,915.22. This represents a 46.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

Elevance Health Trading Up 0.8 %

NYSE ELV opened at $397.48 on Thursday. Elevance Health, Inc. has a one year low of $391.02 and a one year high of $567.26. The company's 50 day moving average price is $466.51 and its 200 day moving average price is $510.83. The firm has a market capitalization of $92.18 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.19 and a beta of 0.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Thursday, October 17th. The company reported $8.37 EPS for the quarter, missing the consensus estimate of $9.66 by ($1.29). The company had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. The business's revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $8.99 earnings per share. On average, sell-side analysts predict that Elevance Health, Inc. will post 32.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Shareholders of record on Thursday, December 5th will be paid a dividend of $1.63 per share. The ex-dividend date is Thursday, December 5th. This represents a $6.52 dividend on an annualized basis and a yield of 1.64%. Elevance Health's dividend payout ratio (DPR) is presently 23.77%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.